Literature DB >> 16218989

Synthesis and biological evaluation of constrained analogues of the opioid peptide H-Tyr-D-Ala-Phe-Gly-NH2 using the 4-amino-2-benzazepin-3-one scaffold.

S Ballet1, A Frycia, J Piron, N N Chung, P W Schiller, P Kosson, A W Lipkowski, D Tourwé.   

Abstract

The synthesis of conformationally restricted dipeptidic moieties 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba)-Gly ([(4S)-amino-3-oxo-1,2,4,5-tetrahydro-1H-2-benzazepin-2-yl]-acetic acid) and 8-hydroxy-4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Hba)-D-Ala ([(4S)-amino-8-hydroxy-3-oxo-1,2,4,5-tetrahydro-benzo[c]azepin-2-yl]-propionic acid) was based on a synthetic strategy that uses an oxazolidinone as an N-acyliminium precursor. Introducing these Aba scaffolds into the N-terminal tetrapeptide of dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2)-induced remarkable shifts in affinity and selectivity towards the opioid mu- and delta-receptors. This paper provides the synthesis and biological in vitro and in vivo evaluation of constricted analogues of the N-terminal tetrapeptide H-Tyr-D-Ala-Phe-Gly-NH2, which is the minimal subunit of dermorphin needed for dermorphin-like opiate activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16218989     DOI: 10.1111/j.1399-3011.2005.00291.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  13 in total

1.  Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.

Authors:  Steven Ballet; Debby Feytens; Koen Buysse; Nga N Chung; Carole Lemieux; Suneeta Tumati; Attila Keresztes; Joost Van Duppen; Josephine Lai; Eva Varga; Frank Porreca; Peter W Schiller; Jozef Vanden Broeck; Dirk Tourwé
Journal:  J Med Chem       Date:  2011-03-17       Impact factor: 7.446

2.  New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.

Authors:  Steven Ballet; Severo Salvadori; Claudio Trapella; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Lucia Negri; Elisa Giannini; Roberta Lattanzi; Dirk Tourwé; Gianfranco Balboni
Journal:  J Med Chem       Date:  2006-06-29       Impact factor: 7.446

3.  Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics.

Authors:  Cecilia Betti; Joanna Starnowska; Joanna Mika; Jolanta Dyniewicz; Lukasz Frankiewicz; Alexandre Novoa; Marta Bochynska; Attila Keresztes; Piotr Kosson; Wioletta Makuch; Joost Van Duppen; Nga N Chung; Jozef Vanden Broeck; Andrzej W Lipkowski; Peter W Schiller; Frans Janssens; Marc Ceusters; François Sommen; Theo Meert; Barbara Przewlocka; Dirk Tourwé; Steven Ballet
Journal:  ACS Med Chem Lett       Date:  2015-10-31       Impact factor: 4.345

4.  Azepinone-Containing Tetrapeptide Analogues of Melanotropin Lead to Selective hMC4R Agonists and hMC5R Antagonist.

Authors:  Olivier Van der Poorten; Krisztina Fehér; Koen Buysse; Debby Feytens; Ioanna Zoi; Steven D Schwartz; José C Martins; Dirk Tourwé; Minying Cai; Victor J Hruby; Steven Ballet
Journal:  ACS Med Chem Lett       Date:  2014-12-03       Impact factor: 4.345

5.  Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist - neurokinin-1 antagonist peptidomimetics.

Authors:  Karel Guillemyn; Patrycia Kleczkowska; Anna Lesniak; Jolanta Dyniewicz; Olivier Van der Poorten; Isabelle Van den Eynde; Attila Keresztes; Eva Varga; Josephine Lai; Frank Porreca; Nga N Chung; Carole Lemieux; Joanna Mika; Ewelina Rojewska; Wioletta Makuch; Joost Van Duppen; Barbara Przewlocka; Jozef Vanden Broeck; Andrzej W Lipkowski; Peter W Schiller; Dirk Tourwé; Steven Ballet
Journal:  Eur J Med Chem       Date:  2014-12-19       Impact factor: 6.514

6.  Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffold.

Authors:  Steven Ballet; Alexander V Mayorov; Minying Cai; Dagmara Tymecka; Kevin B Chandler; Erin S Palmer; Karolien Van Rompaey; Aleksandra Misicka; Dirk Tourwé; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2007-02-09       Impact factor: 2.823

7.  Variation of the net charge, lipophilicity, and side chain flexibility in Dmt(1)-DALDA: Effect on Opioid Activity and Biodistribution.

Authors:  Alexandre Novoa; Sylvia Van Dorpe; Evelien Wynendaele; Mariana Spetea; Nathalie Bracke; Sofie Stalmans; Cecilia Betti; Nga N Chung; Carole Lemieux; Johannes Zuegg; Matthew A Cooper; Dirk Tourwé; Bart De Spiegeleer; Peter W Schiller; Steven Ballet
Journal:  J Med Chem       Date:  2012-11-12       Impact factor: 7.446

8.  χ-Space Screening of Dermorphin-Based Tetrapeptides through Use of Constrained Arylazepinone and Quinolinone Scaffolds.

Authors:  Olivier Van der Poorten; Robin Van Den Hauwe; Emilie Eiselt; Cecilia Betti; Karel Guillemyn; Nga N Chung; François Hallé; Frédéric Bihel; Peter W Schiller; Dirk Tourwé; Philippe Sarret; Louis Gendron; Steven Ballet
Journal:  ACS Med Chem Lett       Date:  2017-10-04       Impact factor: 4.345

9.  Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.

Authors:  Karel Guillemyn; Joanna Starnowska; Camille Lagard; Jolanta Dyniewicz; Ewelina Rojewska; Joanna Mika; Nga N Chung; Valérie Utard; Piotr Kosson; Andrzej W Lipkowski; Lucie Chevillard; Pol Arranz-Gibert; Meritxell Teixidó; Bruno Megarbane; Dirk Tourwé; Frédéric Simonin; Barbara Przewlocka; Peter W Schiller; Steven Ballet
Journal:  J Med Chem       Date:  2016-04-14       Impact factor: 7.446

10.  In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera.

Authors:  Karel Guillemyn; Patrycja Kleczkowska; Alexandre Novoa; Bart Vandormael; Isabelle Van den Eynde; Piotr Kosson; Muhammad Faheem Asim; Peter W Schiller; Mariana Spetea; Andrzej W Lipkowski; Dirk Tourwé; Steven Ballet
Journal:  Mol Brain       Date:  2012-01-30       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.